On November 9, 2017, the FDA approved for use a new hepatitis B vaccine HEPLISAV-B.
The good news is twofold. First, efficacy was higher in a head-to-head trial with EnergIx-B, 95% versus 81%, a statistically significant difference in a trial involving about 10,000 participants. Second, the new vaccine is a two-dose series with the second dose given 1 month after the first. The three-dose series for the other two approved hepatitis B vaccines each take six months to complete. The more doses in a vaccine series and the longer the time interval between the first and last dose, the lower the completion rate for the series and the longer the intervals of undervaccinated status.
According to a study done over an 8-year period, what percentage of adults fail to complete the current three-dose hepatitis B series of vaccines within 12 months?
Please click "next" for answer and discussion.